Objective To investigate the effects of high flux hemodialysis on cardiac structure and function in maintenance hemodialysis patients, and to study the possible mechanism. Methods The study was prospective and self-controlled.A totol of 88 patients on maintainance low flux hemodialysis were recruited, after changing to a high flux hemodialysis treatment for 24 months. Their cardiac structure and function were compared by echocardiography respectively. Serum creatinine(SCr), blood urea nitrogen(BUN), serum phosphorus(P), calcium(Ca), intact parathyroid hormone(iPTH), β2- microglobulin(β2-MG),high sensitivity C-reactive protein(hs-CRP), albumin(ALB),and hemoglobin(Hb) levels were determined after the switch for 0, 12 and 24 months. Results There was no significant atteration of the cardiac function indexes of LAD, LVPWT, IVST, LVEF, E/A, compared with before after 12 months’ treatment of HFHD.But patients with HDHF on treatment for 24 months, had significant alteration of the cardiac function indexes of LAD, LVDd, LVPWT, IVST, LVEF compared with before (P＜0.05). In patients with HDHF on the treatment for 24 months, the clinical indicators of serum ALB, CH, TG, HDL, LDL, Scr, BUN, hs-CRP, DBP, MAP had no differences before and after changing to HFHD, serum Hb and Ca significantly increased after changing to HFHD(P＜0.05),serum P, iPTH、β2-MG have significantly decreased after changing to HFHD(P＜0.05). Conclusions In MHD patients universally exists left ventricular hypertrophy. Although HFHD may remove plasma medium molecule and macromolecule toxins such as β2-MG, inflammation substance and improve uremia in the body, it can not improve left ventricular diastolic function.
Key words
high flux hemodialysis /
left ventricular structure and function /
serum phosphorus /
intact parathyroid hormone /
high sensitivity C-reactive protein
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Dhar S, Pressman G S, Subramanian S, et al. Natriuretic peptides and heart failure in the patient with chronic kidney disease: a review of current evidence[J]. Postgrad Med J, 2009, 85(1004):299-302.
[2] US Renal Data System. Overall hospitalization and mortality[J]. Am J Kidney Dis, 2003, 42(6 Suppl 5):S1-1S230.
[3] Asci G, Tz H, Ozkahya M, et al. The impact of membrane permeability and dialysate purity on cardiovascular outcomes[J]. J Am Soc Nephrol, 2013,24(6):1014-1023.
[4] Boure T, Vanholder R. Biochemical and clinical evidence for uremic toxicity[J]. Artif Organs, 2004,28(3):248-253.
[5] Patel R K, Oliver S, Mark P B, et al. Determinants of left ventricular mass and hypertrophy in hemodialysis patients assessed by cardiac magnetic resonance imaging[J]. Clin J Am Soc Nephrol, 2009,4(9):1477-1483.
[6] Ok E, Asci G, Toz H, et al. Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study[J]. Nephrol Dial Transplant, 2013,28(1):192-202.
[7] Traut M, Haufe C C, Eismann U, et al. Increased binding of beta-2-microglobulin to blood cells in dialysis patients treated with high-flux dialyzers compared with low-flux membranes contributed to reduced beta-2-microglobulin concentrations(Results of a cross-over study)[J]. Blood Purif, 2007,25(5-6):432-440.
[8] Duran M, Unal A, Inanc M T, et al. Hemodialysis does not impair ventricular functions over 2 years[J]. Hemodial Int, 2011,15(3):334-340.
[9] Zumrutdal A, Sezer S, Demircan S, et al. Cardiac troponin I and beta 2 microglobulin as risk factors for early-onset atherosclerosis in patients on haemodialysis[J]. Nephrology (Carlton), 2005,10(5):453-458.
[10] Cheung A K, Rocco M V, Yan G, et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study[J]. J Am Soc Nephrol, 2006,17(2):546-555.
[11] 刘 红,常 明,刘书馨, 等. 高通量透析对尿毒症患者心血管系统的影响及可能的机制探讨[J]. 大连医科大学学报, 2012,34(6):565-568.
[12] 徐丰博,孙 懿,刘惠兰. 高通量血液透析对维持性血液透析患者微炎症状态的影响[J]. 中国血液净化, 2011,10(3):133-135.
[13] 宋张红, 于为民. 高通量血液透析对终末期肾病患者炎症介质及心脏功能的影响[J]. 中国医药, 2013,8(z1):26-28.
PDF(690 KB)
